Zymeworks BC Inc’s filing revealed that its Director EcoR1 Capital, LLC acquired Company’s shares for reported $1.69 million on Jan 16 ’25. In the deal valued at $13.88 per share,121,681 shares were bought. As a result of this transaction, EcoR1 Capital, LLC now holds 15,700,413 shares worth roughly $188.4 million.
Then, EcoR1 Capital, LLC bought 19,748 shares, generating $273,998 in total proceeds. Upon buying the shares at $13.87, the Director now owns 15,720,161 shares.
Before that, EcoR1 Capital, LLC bought 74,125 shares. Zymeworks BC Inc shares valued at $992,875 were divested by the Director at a price of $13.39 per share. As a result of the transaction, EcoR1 Capital, LLC now holds 15,485,203 shares, worth roughly $185.82 million.
JP Morgan upgraded its Zymeworks BC Inc [ZYME] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in early November from “a Market perform” to “an Outperform”. Wells Fargo also remained covering ZYME and has decreased its forecast on November 01, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating.
Price Performance Review of ZYME
On Friday, Zymeworks BC Inc [NASDAQ:ZYME] saw its stock fall -1.07% to $12.00. Over the last five days, the stock has lost -10.45%. Zymeworks BC Inc shares have fallen nearly -18.03% since the year began. Nevertheless, the stocks have risen 0.17% over the past one year. While a 52-week high of $17.70 was reached on 01/03/25, a 52-week low of $7.97 was recorded on 03/07/25. SMA at 50 days reached $14.13, while 200 days put it at $12.28.
Levels Of Support And Resistance For ZYME Stock
The 24-hour chart illustrates a support level at 11.71, which if violated will result in even more drops to 11.42. On the upside, there is a resistance level at 12.25. A further resistance level may holdings at 12.50. The Relative Strength Index (RSI) on the 14-day chart is 34.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.78%. Stochastics %K at 16.40% indicates the stock is a buying.
The most recent change occurred on January 04, 2023 when H.C. Wainwright resumed its ‘”a Neutral”‘ rating for the stock and retained the price target to $8.
